CD62L Expression Is Associated With
Burgess M, Mollee P, Singhania, et al.
Key Points:
- Investigators studied complex microenvironmental interactions resulting in CLL cell resistance to apoptosis by profiling immunophoenotypic changes occurring in long-term CLL PBMC cultures
- Most highly upregulated marker was CD62L (L-selectin, a homing receptor)
- CD62L expression present in proliferation and survival niches involved in CLL in bone marrow and lymph nodes
- CD62L blocking antibody resulted in significant loss of CLL cell survival; however, PBMCs from normal healthy controls unaffected
- CD62L antibody treatment caused specific 49% reduction of CD5+/CD19+ cells when compared to untreated PBMCs
- Investigators also demonstrated significant increase in cytotoxic responses with combination of anti-CD62L treatment fludarabine and/or mafosfamide.
Implications:
- CD62L is novel prosurvival effector that may represent attractive therapeutic target in CLL.
View the original abstract on the ASH website.
